首页> 外文期刊>Pathologica. >High FOXA1 Immunohistochemical Expression Level Associates with Mucinous Histology, Favourable Clinico-pathological Prognostic Parameters and Survival Advantage in Epithelial Ovarian Cancer
【24h】

High FOXA1 Immunohistochemical Expression Level Associates with Mucinous Histology, Favourable Clinico-pathological Prognostic Parameters and Survival Advantage in Epithelial Ovarian Cancer

机译:高福氏免疫组织化学表达水平与粘液组织学,有利的临床病理预后参数和上皮卵巢癌中的存活优势

获取原文
           

摘要

Background. Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). Aim. This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its association with clinico-pathological parameters in EOC including overall and diseasefree survivals (OS, DFS) and patient’s outcome. Methods. Patient’s socio-epidemiologic, clinical, radiological, laboratory, surgical, and follow-up data were collected. After histopathologic typing, grading and staging, FOXA1 IHC expression was scored in 98 EOC specimens. Clinico-pathological associations were investigated in high-and low-FOXA1 expression groups using appropriate statistical methods. Kaplan?Meier method was used for survival analysis. Results. FOXA1 tumor cell nuclear staining was detected in 63.3% of EOC with weak, moderate and strong scores (28.6%, 12.2% and 22.5% respectively). Comparing highand low-expression groups (34.7% and 65.3% respectively), high FOXA1 was associated with larger tumors, low mean serum CA-125, tumor histopathology (mucinous and lowgrade serous), type I EOC, limited tumor’s anatomical extent, absence of nodal or distant metastases and omental nodules, earlier FIGO stages, non-recurrent tumors and survival advantage with longer and OS and DFS (all p ≤ 0.05). Independent predictors of high FOXA1 expression included: omental nodules, tumor’s anatomical extent and tumor’s size (p ≤ 0.001, = 0.046 and = 0.023 respectively). Conclusion. FOXA1 is frequently expressed in EOC notably mucinous and low-grade serous carcinomas in association with favorable prognostic clinico-pathological parameters and longer OS and DFS. It likely has a suppressor function in EOC and could be recommended as a prognostic and therapeutic biomarker.
机译:背景。 FORKHEAD盒(FOX)A1是已经在各种人类癌症中进行了研究的潜在治疗生物标志物。关于上皮性卵巢癌(EOC)的FOXA1生物学作用存在有限的数据。目标。该研究评估了FoxA1免疫组织化学(IHC)的表达,并评估其与Eoc中的临床病理参数的关联,包括总体和疾病患者(OS,DFS)和患者的结果。方法。患者的社会流行病学,临床,放射,实验室,手术和随访数据被收集。组织病理学分型,分级和分期后,FOXA1 IHC表达在98个EoC标本中得分。使用适当的统计方法在高和低FOXA1表达组中研究临床病理学缔合。 Kaplan?Meier方法用于存活分析。结果。在63.3%的EOC中检测到FOXA1肿瘤细胞核染色,弱,中度和强度分别分别为28.6%,12.2%和22.5%)。比较高于低表达群(分别为34.7%和65.3%),高狐狸1与肿瘤较大,平均血清Ca-125,肿瘤组织病理学(粘液和低级浆液),I型EOC,肿瘤有限的解剖程度,没有Nodal或远处转移和题位结节,早期的FOGO阶段,不经常性肿瘤和生存优势,较长,OS和DF(所有P≤0.05)。 High FoxA1表达的独立预测因子包括:甘露结节,肿瘤的解剖程度和肿瘤的大小(P≤0.001分别= 0.046且= 0.023)。结论。 FOXA1经常以EOC恒定的粘液和低级浆液癌,与良好的预后临床病理参数和较长的OS和DFS相关联。它可能在EOC中具有抑制作用功能,可以推荐为预后和治疗生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号